Results 81 to 90 of about 786,314 (373)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)

BMC Pharmacology and Toxicology, 2023
Abstract Background Pertuzumab is widely used for the treatment of HER2 + breast cancer. But its safety in the real world should be continuously monitored. So, we evaluated the safety of pertuzumab by pharmacovigilance analyze based on related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS) and ...
Zou, Shu-peng, Yang, Hai-yun, Ouyang, Meng-ling, Cheng, Qian, Shi, Xuan, Sun, Ming-hui   +5 more
openaire   +2 more sources

From omics to AI—mapping the pathogenic pathways in type 2 diabetes

FEBS Letters, EarlyView.
Integrating multi‐omics data with AI‐based modelling (unsupervised and supervised machine learning) identify optimal patient clusters, informing AI‐driven accurate risk stratification. Digital twins simulate individual trajectories in real time, guiding precision medicine by matching patients to targeted therapies.
Siobhán O'Sullivan, Lu Qi, Pierre Zalloua   +2 more
wiley   +1 more source

Bayesian model selection in logistic regression for the detection of adverse drug reactions [PDF]

, 2015
Motivation: Spontaneous adverse event reports have a high potential for detecting adverse drug reactions. However, due to their dimension, exploring such databases requires statistical methods.
Marbac, Matthieu, Sedki, Mohammed, Tubert-Bitter, Pascale   +2 more
core   +2 more sources

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

Journal of Clinical Medicine, 2021
Background: Cardiovascular safety concerns for major cardiovascular events (MACE) were raised during the clinical trials of romosozumab. We aimed to evaluate the cardiovascular safety profile of romosozumab in a large pharmacovigilance database. Methods:
Annika Vestergaard Kvist, Junaid Faruque, E. Vallejo-Yagüe, S. Weiler, E. Winter, A. M. Burden   +5 more
semanticscholar   +1 more source

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

FEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura, Lixiang Wang, Nao Hasuzawa, Ayako Nagayama, Sawako Moriyama, Kenji Ashida, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto   +8 more
wiley   +1 more source

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study

Heliyon
Background: Alpelisib was approved for treatment of breast cancer. We assessed the safety signals associated with alpelisib by data mining the FDA pharmacovigilance database. Methods: Data from the second quarter of 2019 to the fourth quarter of 2022 had
Yun Li, Hang Li, Zhongyuan Xiang
doaj   +1 more source

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

Cardiovascular Diabetology, 2021
Background Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF).
B. Bonora, E. Raschi, A. Avogaro, G. Fadini   +3 more
semanticscholar   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Transurethral radiofrequency collagen denaturation for the treatment of women with urinary incontinence [PDF]

, 2015
Peer reviewedPublisher ...
Alonso-Coello, Pablo, Dahm, Philipp, Han, Julia, Kang, Diana, Moy, M. Louis, Neuberger, Molly M., Wallace, Sheila Ann   +6 more
core   +1 more source

Summary of COVID-19 vaccine-related reports in the vaccine adverse event reporting system

Journal of Research in Pharmacy Practice, 2021
Identification of the severe acute respiratory syndrome coronavirus 2 in humans toward the end of 2019 triggered a rapid, intensive effort to develop a vaccine. Among the first three COVID-19 vaccines granted emergency use authorization by the U. S. Food
Alice C Ceacareanu, Zachary A. P. Wintrob   +1 more
doaj   +1 more source